Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Christopher Powell

Urology Carrollton, GA Medical Doctor

NPI 1205156320 CMS profile 653871

West Georgia Urology Associates, 150 Clinic Ave Ste 202, Carrollton, GA 30117

Open in the dashboard

General payments

$2,246

72 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Christopher Powell of Carrollton, GA is reported in the CMS Open Payments database as having received $2,246 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $98 1
2023 General $97 5
2022 General $201 13
2021 General $232 12
2020 General $175 13
2019 General $1,442 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Powell
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Christopher Powell were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Christopher Powell Urology median Middle half National median
2019 $1,442 $480 $147–$1,201 $163
2020 $175 $246 $87–$645 $114
2021 $232 $358 $111–$1,000 $132
2022 $201 $476 $143–$1,263 $149
2023 $97 $560 $168–$1,461 $160
2024 $98 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. NeoTract Inc. $1,027 3 payments
  2. Astellas Pharma US Inc $416 24 payments
  3. Dendreon Pharmaceuticals LLC $183 9 payments
  4. Intuitive Surgical, Inc. $122 2 payments
  5. Endo Pharmaceuticals Inc. $71 4 payments
  6. Pfizer Inc. $57 4 payments
  7. Blue Earth Diagnostics Limited $51 2 payments
  8. Janssen Biotech, Inc. $47 3 payments
  9. Axonics Modulation Technologies, Inc. $46 3 payments
  10. Boston Scientific Corporation $44 3 payments
  11. Other $182 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,442 64 payments
  2. Travel and Lodging $760 1 payment
  3. Education $44 7 payments
Products named General payments · program years 2019–2024
  1. UROLIFT $1,027 3 payments
  2. MYRBETRIQ $416 24 payments
  3. XTANDI $366 21 payments
  4. PROVENGE $183 9 payments
  5. Da Vinci Surgical System $122 2 payments
  6. XIAFLEX $71 4 payments
  7. GEMTESA $50 3 payments
  8. ERLEADA $47 3 payments
  9. AVEED $39 2 payments
  10. FOUNDATIONONE LIQUID CDX $34 1 payment
  11. Other $413 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,528

Median for Urology: 1,053

Drug cost

$165,064

Median for Urology: $101,464

Branded share of claims

24%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orgovyx Relugolix Brand 20 $50,939
Myrbetriq Mirabegron Brand 66 $41,199
Gemtesa Vibegron Brand 44 $40,495
Xyosted Testosterone Enanthate Brand 13 $7,900
Tamsulosin Hcl Generic 517 $6,871
Finasteride Generic 432 $5,954
Potassium Citrate Er Potassium Citrate Brand 30 $3,721
Testosterone Cypionate Generic 47 $1,620
Fosfomycin Tromethamine Generic 23 $1,565
Testosterone Generic 18 $1,461

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$106,544

Of which drugs: $20,986

Medicare patients

541

Average age 75

Services billed

5,115

133 women, 408 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 35%
Chronic kidney disease 33%
Cancer 27%
Atrial fibrillation 22%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 17 91 $12,472

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record